View Older Stories

May 19, 2026 06:00PM Onco-Innovations Reports Continued Advancement of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for ONC010 Development Program

May 15, 2026 06:00PM Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate

May 12, 2026 06:00PM Onco-Innovations Announces Initiation of Research Collaboration within PROmAI

May 8, 2026 06:00PM Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology

May 5, 2026 06:00PM Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation

May 1, 2026 06:00PM Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies

Apr 28, 2026 06:00PM Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program

Apr 23, 2026 06:00PM Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies

Apr 21, 2026 06:00PM Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program

Apr 17, 2026 07:00PM Onco-Innovations names new medical officer and R&D chief

Apr 17, 2026 07:00PM Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development

Apr 7, 2026 06:00PM Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy

Mar 12, 2026 05:00PM Onco-Innovations closes $1.2 million private placement financing

Mar 12, 2026 05:00PM Onco-Innovations Announces Closing of Private Placement

Feb 12, 2026 09:01AM Onco-Innovations amends private placement pricing to $0.65 per unit

Feb 12, 2026 09:00AM Onco-Innovations Announces Amendment to Private Placement Pricing

Feb 4, 2026 06:00PM Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus

Jan 23, 2026 07:00PM Onco-Innovations plans $2 million private placement at $0.88 per unit

Jan 23, 2026 07:00PM Onco-Innovations Announces Private Placement

Jan 21, 2026 06:00PM Onco-Innovations Engages i2i Marketing Group Engagement for Market Awareness Services

Dec 9, 2025 06:00PM Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care

Dec 7, 2025 03:00AM Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering

Nov 25, 2025 04:30PM Onco-Innovations Attends University of Alberta's 2025 Innovation Awards

Nov 20, 2025 07:30PM Onco-Innovations begins scale-up work for cancer drug with Dalton Pharma

Nov 20, 2025 07:30PM Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies

Nov 18, 2025 06:00PM Onco-Innovations Advances AI and Quantum Drug Discovery with Kuano Collaboration to Accelerate PNKP Inhibitor Technology Development

Nov 7, 2025 06:00PM Onco-Innovations' Inka Health Publishes Framework on Transportability of Real-World Evidence and Use in Health Technology Assessment

Oct 31, 2025 06:00PM Onco-Innovations Provides Shareholder Update Following Cboe Canada Investor Spotlight

Oct 30, 2025 09:00PM Onco-Innovations appoints Jared Rushton to board of directors

Oct 30, 2025 09:00PM Onco-Innovations Appoints Jared Rushton to Board of Directors

Oct 27, 2025 05:15PM Onco-Innovations closes $2 million private placement

Oct 27, 2025 05:15PM Onco-Innovations Announces Closing of Private Placement

Oct 14, 2025 08:00PM Onco-Innovations plans $2 million private placement offering

Oct 14, 2025 08:00PM Onco-Innovations Announces Private Placement

Sep 29, 2025 12:00AM Onco-Innovations Advances Preclinical Program as Nucro-Technics Begins Analytical Development for PNKP Technology

Sep 22, 2025 05:00PM AMN Healthcare prices $400 million senior notes offering

Sep 22, 2025 05:00PM Onco-Innovations Appoints Dr. Michael Lock to Scientific & Clinical Advisory Board

Sep 19, 2025 06:00PM Onco-Innovations Commences Activities to Manufacture Nanoparticle Formulation with Dalton Pharma to Supply Preclinical Animal Studies

Sep 12, 2025 06:00PM Onco-Innovations to Chair Colorectal Cancer Canada Precision Oncology Forum Driving the Future of Cancer Care

Aug 15, 2025 09:15AM Onco-Innovations Announces 90% of $0.60 Warrants Have Been Exercised

Aug 13, 2025 05:01PM Onco-Innovations closes $400,000 private placement

Aug 13, 2025 05:00PM Onco-Innovations Announces Closing of Private Placement

Aug 4, 2025 04:05PM Onco-Innovations Advances Progress Towards First-in-Human Trial with Avance Clinical Start-Up Agreement

Jul 30, 2025 06:00PM Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms

Jul 29, 2025 09:30PM Onco-Innovations plans $400,000 private placement and stock grants

Jul 29, 2025 09:30PM Onco-Innovations Announces Private Placement

Jul 11, 2025 06:00PM Onco-Innovations Signs Agreement with Redwood AI to Advance Discovery and Evaluation of Its PNKP Inhibitor Technology

Jul 4, 2025 06:00PM Onco-Innovations Enters Agreement with Nucro-Technics for IND-Enabling Studies, Taking a Key Step Toward Human Trials

Jul 2, 2025 06:30PM Onco-Innovations CEO Highlights Strategic Milestones and R&D Progress in Special Investors' Conference Call

Jun 25, 2025 06:00PM Onco-Innovations' CEO to Host Special Investors' Conference Call on Wednesday, July 2, 2025

View Older Stories